{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:51:29Z","timestamp":1776351089835,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Santander Scolarships","award":["Financial Aid for Postdoctoral Research Staff 2025\u2019 program"],"award-info":[{"award-number":["Financial Aid for Postdoctoral Research Staff 2025\u2019 program"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03796-9","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:33:26Z","timestamp":1774010006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methylprednisolone pulses are associated with faster remission in Giant Cell Arteritis: a multicentre inception cohort study"],"prefix":"10.1186","volume":"28","author":[{"given":"Rom\u00e1n","family":"Fern\u00e1ndez-Guiti\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Royuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Tornero-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Aus\u00edn-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Perales-Fraile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Garc\u00eda-Guijarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mart\u00ednez-Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ram\u00edrez-Sanci\u00f1ena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Larrea-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Lucena","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca Arenas","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Garc\u00eda-Guadix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Cristina","family":"Toma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Nic\u00e1s-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda Basauli","family":"Felices","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s Moreno","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Moreno-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"3796_CR1","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454\u201361. https:\/\/doi.org\/10.1002\/art.24459.","journal-title":"Arthritis Rheum"},{"key":"3796_CR2","doi-asserted-by":"publisher","unstructured":"Ponte C, Grayson PC, Robson JC et al. 2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81:1647\u201353. https:\/\/doi.org\/10.1136\/ard-2022-223480","DOI":"10.1136\/ard-2022-223480"},{"key":"3796_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/jnnp-2014-307614","volume":"86","author":"M Samson","year":"2015","unstructured":"Samson M, Jacquin A, Audia S, et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry. 2015;86:216\u201321. https:\/\/doi.org\/10.1136\/jnnp-2014-307614.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3796_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MD.0b013e3181af4518","volume":"88","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis. Medicine. 2009;88:227\u201335. https:\/\/doi.org\/10.1097\/MD.0b013e3181af4518.","journal-title":"Medicine"},{"key":"3796_CR5","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2665-9913(23)00300-4","volume":"6","author":"KSM van der Geest","year":"2024","unstructured":"van der Geest KSM, Sandovici M, Bley TA, et al. Large vessel giant cell arteritis. Lancet Rheumatol. 2024;6:e397\u2013408. https:\/\/doi.org\/10.1016\/S2665-9913(23)00300-4.","journal-title":"Lancet Rheumatol"},{"key":"3796_CR6","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2665-9913(24)00024-9","volume":"6","author":"P Bosch","year":"2024","unstructured":"Bosch P, Espigol-Frigol\u00e9 G, Cid MC, et al. Cranial involvement in giant cell arteritis. Lancet Rheumatol. 2024;6:e384\u201396. https:\/\/doi.org\/10.1016\/S2665-9913(24)00024-9.","journal-title":"Lancet Rheumatol"},{"key":"3796_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318\u201323. https:\/\/doi.org\/10.1136\/ard.2008.088351.","journal-title":"Ann Rheum Dis"},{"key":"3796_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672.","journal-title":"Ann Rheum Dis"},{"key":"3796_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Care Res (Hoboken). 2003;49:703\u20138. https:\/\/doi.org\/10.1002\/art.11388.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3796_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377:317\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1613849.","journal-title":"N Engl J Med"},{"key":"3796_CR11","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","volume":"3","author":"JH Stone","year":"2021","unstructured":"Stone JH, Han J, Aringer M, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021;3:e328\u201336. https:\/\/doi.org\/10.1016\/S2665-9913(21)00038-2.","journal-title":"Lancet Rheumatol"},{"key":"3796_CR12","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","volume":"392","author":"D Blockmans","year":"2025","unstructured":"Blockmans D, Penn SK, Setty AR, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025;392:2013\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2413449.","journal-title":"N Engl J Med"},{"key":"3796_CR13","doi-asserted-by":"publisher","unstructured":"Christ L, Seitz L, Scholz G et al. Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three-year follow-up. Rheumatology. Published Online First: 6 June 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf317","DOI":"10.1093\/rheumatology\/keaf317"},{"key":"3796_CR14","doi-asserted-by":"publisher","unstructured":"Waljee AK, Rogers MAM, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;j1415. https:\/\/doi.org\/10.1136\/bmj.j1415.","DOI":"10.1136\/bmj.j1415"},{"key":"3796_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/acr.24632","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken). 2021;73:1071\u201387. https:\/\/doi.org\/10.1002\/acr.24632.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3796_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology. 2020;59:e1\u201323. https:\/\/doi.org\/10.1093\/rheumatology\/kez672.","journal-title":"Rheumatology"},{"key":"3796_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ncprheum0898","volume":"4","author":"C Stahn","year":"2008","unstructured":"Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4:525\u201333. https:\/\/doi.org\/10.1038\/ncprheum0898.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"3796_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","volume":"16","author":"G Ruiz-Irastorza","year":"2017","unstructured":"Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16:826\u201332. https:\/\/doi.org\/10.1016\/j.autrev.2017.05.017.","journal-title":"Autoimmun Rev"},{"key":"3796_CR19","doi-asserted-by":"publisher","first-page":"e001562","DOI":"10.1136\/lupus-2025-001562","volume":"12","author":"G Ruiz-Irastorza","year":"2025","unstructured":"Ruiz-Irastorza G, Mar\u00edn-Garc\u00eda B, Due\u00f1a-Bartolom\u00e9 L, et al. Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts. Lupus Sci Med. 2025;12:e001562. https:\/\/doi.org\/10.1136\/lupus-2025-001562.","journal-title":"Lupus Sci Med"},{"key":"3796_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/acr.25334","volume":"76","author":"G Ruiz-Irastorza","year":"2024","unstructured":"Ruiz-Irastorza G, Paredes\u2010Ruiz D, Herrero\u2010Galvan M, et al. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus\u2010Cruces\u2010Bordeaux Inception Cohort. Arthritis Care Res (Hoboken). 2024;76:1132\u20138. https:\/\/doi.org\/10.1002\/acr.25334.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3796_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/rheumatology\/keab597","volume":"61","author":"LS Hoff","year":"2022","unstructured":"Hoff LS, de Souza FHC, Miossi R, et al. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Rheumatology. 2022;61:1579\u201388. https:\/\/doi.org\/10.1093\/rheumatology\/keab597.","journal-title":"Rheumatology"},{"key":"3796_CR22","doi-asserted-by":"publisher","first-page":"152164","DOI":"10.1016\/j.semarthrit.2023.152164","volume":"59","author":"V Moreno-Torres","year":"2023","unstructured":"Moreno-Torres V, Mart\u00edn-Iglesias D, Vivero F, et al. Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2023;59:152164. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152164.","journal-title":"Semin Arthritis Rheum"},{"key":"3796_CR23","doi-asserted-by":"publisher","first-page":"105641","DOI":"10.1016\/j.jbspin.2023.105641","volume":"91","author":"R For\u00e9","year":"2024","unstructured":"For\u00e9 R, Liozon E, Dumonteil S, et al. BOB-ACG study: Pulse methylprednisolone to prevent bilateral ophthalmologic damage in giant cell arteritis. A multicentre retrospective study with propensity score analysis. Joint Bone Spine. 2024;91:105641. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105641.","journal-title":"Joint Bone Spine"},{"key":"3796_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf499","author":"A Soto-Peleteiro","year":"2025","unstructured":"Soto-Peleteiro A, Hern\u00e1ndez-Rodr\u00edguez J, Raad F, et al. Methylprednisolone plus MTX-based regime vs prednisone-based standard of care for GCA: a propensity score study. Rheumatology Published Online First: 16 September. 2025. https:\/\/doi.org\/10.1093\/rheumatology\/keaf499.","journal-title":"Rheumatology Published Online First: 16 September"},{"key":"3796_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.medcli.2023.04.004","volume":"161","author":"E S\u00e1nchez-Chica","year":"2023","unstructured":"S\u00e1nchez-Chica E, Mart\u00ednez-Urbistondo M, Guti\u00e9rrez Rojas \u00c1, et al. Prevalence and impact of cerebrovascular risk factors in patients with giant cell arteritis: An observational study from the Spanish national registry. Med Clin (Barc). 2023;161:20\u20133. https:\/\/doi.org\/10.1016\/j.medcli.2023.04.004.","journal-title":"Med Clin (Barc)"},{"key":"3796_CR26","first-page":"1484","volume":"27","author":"P Chevalet","year":"2000","unstructured":"Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1484\u201391.","journal-title":"J Rheumatol"},{"key":"3796_CR27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/jcm11071799","volume":"11","author":"A R\u00e9gent","year":"2022","unstructured":"R\u00e9gent A, Mouthon L. Treatment of Giant Cell Arteritis (GCA). J Clin Med. 2022;11:1799. https:\/\/doi.org\/10.3390\/jcm11071799.","journal-title":"J Clin Med"},{"key":"3796_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA, Hern\u00e1ndez-Garc\u00eda C, Morado IC, et al. Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone. Ann Intern Med. 2001;134:106\u201314. https:\/\/doi.org\/10.7326\/0003-4819-134-2-200101160-00010.","journal-title":"Ann Intern Med"},{"key":"3796_CR29","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/jcm11061588","volume":"11","author":"S Casta\u00f1eda","year":"2022","unstructured":"Casta\u00f1eda S, Prieto-Pe\u00f1a D, Vicente-Rabaneda EF, et al. Advances in the Treatment of Giant Cell Arteritis. J Clin Med. 2022;11:1588. https:\/\/doi.org\/10.3390\/jcm11061588.","journal-title":"J Clin Med"},{"key":"3796_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1210\/endrev\/bnad016","volume":"44","author":"R Pofi","year":"2023","unstructured":"Pofi R, Caratti G, Ray DW, et al. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad ? Endocr Rev. 2023;44:975\u20131011. https:\/\/doi.org\/10.1210\/endrev\/bnad016.","journal-title":"Endocr Rev"},{"key":"3796_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40744-025-00778-2","volume":"12","author":"JR Curtis","year":"2025","unstructured":"Curtis JR, Kruzikas DT, Romero A, et al. Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids. Rheumatol Ther. 2025;12:835\u201354. https:\/\/doi.org\/10.1007\/s40744-025-00778-2.","journal-title":"Rheumatol Ther"},{"key":"3796_CR32","doi-asserted-by":"publisher","first-page":"e16816","DOI":"10.1097\/MD.0000000000016816","volume":"98","author":"V Alende-Castro","year":"2019","unstructured":"Alende-Castro V, Alonso-Sampedro M, Vazquez-Temprano N, et al. Factors influencing erythrocyte sedimentation rate in adults. Medicine. 2019;98:e16816. https:\/\/doi.org\/10.1097\/MD.0000000000016816.","journal-title":"Medicine"},{"key":"3796_CR33","first-page":"2351","volume":"27","author":"MH Wener","year":"2000","unstructured":"Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol. 2000;27:2351\u20139.","journal-title":"J Rheumatol"},{"key":"3796_CR34","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/rheumatology\/keae459","volume":"64","author":"H Henningson","year":"2025","unstructured":"Henningson H, Hammar B, Mohammad AJ. The use of intravenous methylprednisolone in giant cell arteritis: a population-based study. Rheumatology. 2025;64:2083\u201390. https:\/\/doi.org\/10.1093\/rheumatology\/keae459.","journal-title":"Rheumatology"},{"key":"3796_CR35","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double\u2010blind, placebo\u2010controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310\u20138. https:\/\/doi.org\/10.1002\/art.22163.","journal-title":"Arthritis Rheum"},{"key":"3796_CR36","first-page":"S","volume":"33","author":"I Les","year":"2015","unstructured":"Les I, Pijo\u00e1n JI, Rodr\u00edguez-\u00c1lvarez R, et al. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol. 2015;33:S\u201390.","journal-title":"Clin Exp Rheumatol"},{"key":"3796_CR37","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736\u201345. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089.","journal-title":"Ann Rheum Dis"},{"key":"3796_CR38","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.autrev.2019.102359","volume":"18","author":"G Ruiz-Irastorza","year":"2019","unstructured":"Ruiz-Irastorza G, Ruiz-Estevez B, Lazaro E, et al. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev. 2019;18:102359. https:\/\/doi.org\/10.1016\/j.autrev.2019.102359.","journal-title":"Autoimmun Rev"},{"key":"3796_CR39","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(21)00578-X.","journal-title":"Lancet"},{"key":"3796_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1803537.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03796-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03796-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03796-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:57:47Z","timestamp":1776347867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03796-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03796-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Puerta de Hierro University Hospital (PI 16\/24), as well as by the local Institutional Review Boards of the participating centers. In accordance with Spanish law and the exemption granted by the Ethics Committee, informed consent was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AGG declares having received honoraria for lectures from Roche. The remaining authors declare they have no conflict of interest or personal relationship that could bias the findings reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}